UBS Group’s Arcadia Biosciences RKDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.11K | Buy |
807
+242
| +43% | +$474 | ﹤0.01% | 9619 |
|
|
2025
Q4 | $1.12K | Sell |
565
-534
| -49% | -$1.97K | ﹤0.01% | 9697 |
|
|
2025
Q3 | $3.81K | Sell |
1,099
-1,445
| -57% | -$5.9K | ﹤0.01% | 9007 |
|
|
2025
Q2 | $11K | Sell |
2,544
-6,016
| -70% | -$23.8K | ﹤0.01% | 8811 |
|
|
2025
Q1 | $25.4K | Sell |
8,560
-5,385
| -39% | -$23.3K | ﹤0.01% | 8060 |
|
|
2024
Q4 | $82.6K | Buy |
13,945
+13,706
| +5,735% | +$56.4K | ﹤0.01% | 6986 |
|
|
2024
Q3 | $652 | Buy |
+239
| New | +$686 | ﹤0.01% | 8854 |
|
|
2024
Q2 | – | Sell |
-2
| Closed | -$4 | – | 9996 |
|
|
2024
Q1 | $4 | Buy |
+2
| New | +$5 | ﹤0.01% | 9155 |
|
|
2023
Q3 | – | Sell |
-5,010
| Closed | -$19.4K | – | 9880 |
|
|
2023
Q2 | $19.4K | Buy |
5,010
+1,801
| +56% | +$9.6K | ﹤0.01% | 6883 |
|
|
2023
Q1 | $24K | Buy |
+3,209
| New | +$34K | ﹤0.01% | 6954 |
|
|
2022
Q4 | – | Sell |
-392
| Closed | -$8K | – | 11068 |
|
|
2022
Q3 | $8K | Buy |
+392
| New | +$13.4K | ﹤0.01% | 8743 |
|
|
2022
Q2 | – | Sell |
-114
| Closed | -$6K | – | 10832 |
|
|
2022
Q1 | $6K | Sell |
114
-204
| -64% | -$9.73K | ﹤0.01% | 8985 |
|
|
2021
Q4 | $13K | Buy |
+318
| New | +$20.7K | ﹤0.01% | 8469 |
|
|
2021
Q2 | – | Sell |
-231
| Closed | -$25K | – | 9744 |
|
|
2021
Q1 | $25K | Buy |
231
+159
| +221% | +$19.5K | ﹤0.01% | 7174 |
|
|
2020
Q4 | $7K | Sell |
72
-22
| -23% | -$2.69K | ﹤0.01% | 7702 |
|
|
2020
Q3 | $11K | Buy |
94
+71
| +309% | +$9.59K | ﹤0.01% | 6780 |
|
|
2020
Q2 | $4K | Buy |
+23
| New | +$3.58K | ﹤0.01% | 7467 |
|
|
2020
Q1 | – | Sell |
-56
| Closed | -$12K | – | 8328 |
|
|
2019
Q4 | $12K | Sell |
56
-41
| -42% | -$8.22K | ﹤0.01% | 7189 |
|
|
2019
Q3 | $18K | Buy |
+97
| New | +$18.6K | ﹤0.01% | 6802 |
|
|
2019
Q2 | – | Sell |
-234
| Closed | -$66K | – | 8109 |
|
|
2019
Q1 | $66K | Buy |
+234
| New | +$48.9K | ﹤0.01% | 5356 |
|
|
2018
Q3 | – | Sell |
-41
| Closed | -$13K | – | 8214 |
|
|
2018
Q2 | $13K | Buy |
41
+12
| +41% | +$6.55K | ﹤0.01% | 6996 |
|
|
2018
Q1 | $28K | Buy |
29
+5
| +21% | +$2.25K | ﹤0.01% | 6152 |
|
|
2017
Q4 | $5K | Buy |
24
+15
| +167% | +$3.25K | ﹤0.01% | 7391 |
|
|
2017
Q3 | $3K | Buy |
+9
| New | +$3.3K | ﹤0.01% | 7401 |
|
|
2016
Q4 | – | Sell |
-5
| Closed | -$7K | – | 7993 |
|
|
2016
Q3 | $7K | Sell |
5
-1
| -17% | -$1.77K | ﹤0.01% | 6994 |
|
|
2016
Q2 | $11K | Buy |
+6
| New | +$10K | ﹤0.01% | 6728 |
|
|
2016
Q1 | – | Sell |
-8
| Closed | -$19K | – | 8074 |
|
|
2015
Q4 | $19K | Sell |
8
-17
| -68% | -$44.3K | ﹤0.01% | 6810 |
|
|
2015
Q3 | $61K | Buy |
+25
| New | +$104K | ﹤0.01% | 5651 |
|
Other funds holding RKDA
AC
SM
VCM
VFT
TRCT
SS
UBS Group's RKDA Position: Q1 2026 in Review
UBS Group increased its Arcadia Biosciences (RKDA) stake by 43% in Q1 2026, buying an estimated $474 and bringing the position to 807 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #9619.
UBS Group first reported a position in RKDA in Q3 2015 and has held it in 28 quarters since. The position peaked at $82.6K in Q4 2024. 16 funds tracked by Wall St. Rank hold RKDA as of Q1 2026.
- UBS Group held 807 shares of Arcadia Biosciences worth $1.11K as of Q1 2026.
- UBS Group bought 242 Arcadia Biosciences shares in Q1 2026, an estimated $474.
- Arcadia Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9619 holding.
- UBS Group first reported a position in Arcadia Biosciences in Q3 2015 and has held it in 28 quarters since.
- UBS Group's Arcadia Biosciences position peaked at $82.6K in Q4 2024.
- 16 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.